STOCK TITAN
  1. Home
  2. News
  3. LSTA

Lisata Therapeutics Inc - LSTA STOCK NEWS

Welcome to our dedicated news page for Lisata Therapeutics (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lisata Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lisata Therapeutics's position in the market.

News
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) receives Orphan Drug Designation from the FDA for LSTA1, a treatment for osteosarcoma, a rare bone cancer. The designation highlights the urgent need for better therapies for patients with osteosarcoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
clinical trial
-
News
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announces CEO's participation in key events in April 2024, including LD Micro Invitational XIV, FORCE Family Office Webinar, Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference, and Immuno-Oncology Summit Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
-
News
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Rhea-AI Summary
Lisata Therapeutics, Inc. receives Rare Pediatric Disease Designation (RPDD) from the FDA for LSTA1, their lead product candidate for osteosarcoma treatment. The designation grants a priority review voucher, potentially reducing review time and increasing market value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.41%
Tags
none
News
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Lisata Therapeutics, Inc. provides a business update and reports financial results for the year ended December 31, 2023. The company affirms its commitment to operational excellence and efficient development, projecting data announcements in the next 12 to 24 months. The Phase 2b ASCEND trial is fully enrolled, with top-line data expected in Q4 2024. Lisata's lead investigational product, LSTA1, shows promise in enhancing delivery of anti-cancer therapies, with ongoing clinical trials in various solid tumor types. Financially, operating expenses decreased by 55.4% in 2023, with a cash runway extending into early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
earnings
-
News
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announces the release of its financial results for the twelve months ending December 31, 2023. The company will host a conference call on February 29, 2024, at 4:30 p.m. Eastern time. Participants can register via a provided link and access dial-in options. A live webcast will be available on Lisata's website for replay for 12 months post-call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
conferences
-
News
Lisata Therapeutics to Present at BIO CEO & Investor Conference
Rhea-AI Summary
Lisata Therapeutics, Inc. (LSTA) announces Dr. David J. Mazzo's presentation at the BIO CEO & Investor Conference on February 26, 2024, focusing on innovative therapies for advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
News
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced that its President and CEO, Dr. David J. Mazzo, will deliver a company presentation at the Sequire Investor Summit on January 24, 2024. The summit will focus on the development of innovative therapies for advanced solid tumors and serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
conferences
-
News
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme. The trial is a double-blind, placebo-controlled, randomized study being conducted across multiple sites in Estonia and Latvia. LSTA1 has been granted orphan drug designation by the U.S. FDA for malignant glioma. The Company is hopeful for the benefits of LSTA1 in treating this aggressive brain tumor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
clinical trial
-
News
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
Rhea-AI Summary
Lisata Therapeutics, Inc. (LSTA) announced the publication of a case report detailing a complete response in a patient with metastatic gastroesophageal adenocarcinoma treated with LSTA1 in combination with standard-of-care therapy. The patient initially achieved a partial response with standard-of-care treatments but achieved a complete response upon the addition of LSTA1. The case report demonstrates the potential of LSTA1 to improve outcomes for patients with a range of advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
none
News
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
Rhea-AI Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) has completed enrollment in the Phase 2b ASCEND study of its novel agent, LSTA1, for the treatment of metastatic pancreatic ductal adenocarcinoma. Top-line data is expected in the fourth quarter of 2024, with complete data by mid-2025. The trial evaluates the efficacy of LSTA1 in combination with standard-of-care gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.6%
Tags
clinical trial
Stock LSTA logo
Lisata Therapeutics Inc

Nasdaq:LSTA

LSTA Rankings

#5067 Ranked by Market Cap
#4732 Ranked by Stock Gains
N/A Ranked by Dividends

LSTA Stock Data

24.09M
6.75M
19%
8.93%
0.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Basking Ridge

About LSTA

caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.